COFEPRIS Generic Drug Approval: Market Impact & Competitive Shift 2025

Key Takeaways

• Accelerated timeline: COFEPRIS's abbreviated pathway reduces generic drug approvals to 45 business days through reliance on Reference Regulatory Authority (RRA) decisions, effective September 1, 2025.
• Recognized authorities: The pathway accepts prior approvals from the U.S. FDA, European EMA, WHO Prequalification Program, Health Canada, and Swissmedic.
• Market impact: Mexico's generic drug market, valued at USD 757.62 million in 2024 and projected to reach USD 1.6 billion by 2032, will see intensified competition from faster market entry.
• Eligibility criteria: Products must demonstrate identical essential characteristics to the RRA-approved version, with foreign authorization issued within the last five years.
• Regulatory alignment: The pathway implements WHO Good Regulatory Practices, reducing duplication while maintaining Mexican regulatory autonomy.

  What Is COFEPRIS's New Abbreviated Pathway?

  COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) introduced an abbreviated regulatory pathway on September 1, 2025, designed to accelerate the registration of generic drugs and medical devices in Mexico. This reliance mechanism allows COFEPRIS to recognize marketing authorizations issued by trusted foreign regulatory authorities, reducing both approval timelines and administrative burden.

  The pathway operates under Mexico's General Health Law and Regulation of Health Supplies. Under this framework, COFEPRIS uses the scientific assessments already conducted by Reference Regulatory Authorities (RRAs) rather than duplicating the full review process. This approach aligns with the World Health Organization's Good Regulatory Practices, which encourage regulatory cooperation and reliance to improve access to medicines.

  Applications submitted through the abbreviated pathway must include comprehensive legal and technical documentation. Requirements include the Certificate of Pharmaceutical Product (CPP), Good Manufacturing Practice (GMP) certificates, and the complete dossier submitted to the reference authority. The foreign authorization must remain valid and have been issued within five years of the Mexican application.

  Which Regulatory Authorities Does COFEPRIS Recognize?

  COFEPRIS maintains a defined list of Reference Regulatory Authorities whose approvals qualify for the abbreviated pathway. These authorities are recognized based on their alignment with international standards for pharmaceutical quality, safety, and efficacy assessments.

  Reference Regulatory Authority	Region	Scope
  U.S. Food and Drug Administration (FDA)	United States	Generic drugs, biosimilars
  European Medicines Agency (EMA)	European Union	Generic drugs, biosimilars
  Health Canada	Canada	Generic drugs
  Swissmedic	Switzerland	Generic drugs
  WHO Prequalification Program	International	Essential medicines

  The inclusion of the WHO Prequalification Program is particularly significant for Mexico, as it facilitates access to affordable generic versions of essential medicines for HIV, malaria, tuberculosis, and other priority diseases. This mechanism supports Mexico's public health procurement policies that favor cost-effective treatment options.

  How Does the 45-Day Approval Timeline Work?

  Under the abbreviated pathway, COFEPRIS commits to issuing a decision within 45 business days for generic drug applications that meet all requirements. This represents a substantial reduction compared to traditional approval timelines, which previously extended to several months or longer depending on the complexity of the application.

  The 45-day timeline applies specifically to the reliance-based review process. COFEPRIS verifies that the product submitted for Mexican approval is identical in essential characteristics—quality, safety, and efficacy—to the version approved by the reference authority. This verification focuses on administrative completeness and manufacturing compliance rather than repeating the full scientific evaluation.

  However, the abbreviated timeline does not apply if applications contain deficiencies requiring additional information. In such cases, the review clock pauses until the applicant provides complete documentation. The pathway also requires that applicants demonstrate compliance with Mexican-specific requirements, including NOM-177-SSA1-2013 for bioequivalence studies when applicable.

  What Is the Expected Market Impact in Mexico?

  Mexico represents Latin America's second-largest pharmaceutical market, valued at approximately $15-17 billion annually. Generic drugs constitute the dominant segment, accounting for over 70% of total prescriptions by volume. The abbreviated approval pathway is expected to intensify competition within this already crowded marketplace.

  According to market analysis, Mexico's generic drug market reached USD 757.62 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.8% through 2032, potentially reaching USD 1.6 billion. The accelerated approval process supports this growth trajectory by enabling faster market entry for both multinational and domestic generic manufacturers.

  Key market dynamics affected by the regulatory change include:

  • Domestic manufacturing: Approximately 90% of generic drugs sold in Mexico are manufactured domestically, ensuring supply chain security and compliance with international quality standards.
  • Patent cliff opportunities: Over 120 small-molecule drugs are expected to lose patent protection in the next 3-4 years, creating substantial opportunities for generic entrants using the abbreviated pathway.
  • Price competition: Faster approval timelines increase competitive pressure on originator brands, potentially driving down prices for both retail and government procurement channels.
  • Complex generics: While simple generics hold approximately 75% market share, complex generics (injectables, inhalers, biosimilars) represent a growing opportunity segment where regulatory reliance can accelerate development.

  What Are the Key Requirements for Manufacturers?

  Manufacturers seeking to utilize COFEPRIS's abbreviated pathway must meet specific eligibility criteria and documentation requirements. Understanding these prerequisites is essential for successful navigation of the reliance mechanism.

  First, the product must be essentially identical to the version approved by the Reference Regulatory Authority. This means identical active pharmaceutical ingredients, dosage forms, strengths, and routes of administration. Any differences in formulation or manufacturing processes may disqualify the application from the abbreviated pathway.

  Second, the foreign marketing authorization must be current and issued within the five years preceding the Mexican application. Expired or withdrawn approvals do not qualify for reliance. The reference approval must also remain valid throughout the COFEPRIS review process.

  Required documentation includes:

  1. Valid Certificate of Pharmaceutical Product (CPP) from the country of reference
  2. Current Good Manufacturing Practice (GMP) certificate from the reference authority or WHO
  3. Complete technical dossier submitted to the reference authority
  4. Proof of bioequivalence (for applicable products) per Mexican NOM-177-SSA1-2013
  5. Stability data supporting Mexican climate conditions
  6. Labeling and packaging materials adapted to Mexican regulatory requirements

  How Does This Align With Global Regulatory Trends?

  COFEPRIS's abbreviated pathway reflects a broader global movement toward regulatory reliance and harmonization. The World Health Organization has actively promoted reliance mechanisms as a strategy to improve access to quality medicines, particularly in resource-constrained settings. This approach recognizes that duplicating regulatory reviews across multiple jurisdictions creates unnecessary delays without enhancing patient safety.

  Several Latin American regulatory agencies have implemented similar reliance pathways. ANMAT in Argentina and ANVISA in Brazil have both established recognition procedures for approvals from reference authorities. COFEPRIS's implementation strengthens regional regulatory harmonization and may encourage other Latin American countries to adopt comparable frameworks.

  The pathway also supports Mexico's participation in the US-Mexico-Canada Agreement (USMCA), which includes provisions for pharmaceutical regulatory cooperation. Nearshoring trends in pharmaceutical manufacturing further amplify the importance of streamlined regulatory processes, as companies seek to expand production capacity in Mexico while maintaining access to U.S. and Canadian markets.

  Frequently Asked Questions

  What is COFEPRIS's new abbreviated pathway for generic drugs?

  COFEPRIS introduced an abbreviated regulatory pathway effective September 1, 2025, that relies on approvals from Reference Regulatory Authorities (FDA, EMA, WHO, Health Canada, Swissmedic) to expedite generic drug approvals to 45 business days.

  Which regulatory authorities does COFEPRIS recognize for reliance?

  COFEPRIS recognizes the U.S. FDA, European EMA, Health Canada, Swissmedic, and WHO Prequalification Program as Reference Regulatory Authorities for its abbreviated approval pathway.

  How will the new COFEPRIS pathway impact Mexico's generic drug market?

  The abbreviated pathway is expected to accelerate market entry for generics in Mexico's $15-17 billion pharmaceutical market, where generics already account for over 70% of prescriptions, intensifying competition and potentially lowering prices.

  What are the eligibility requirements for COFEPRIS's reliance pathway?

  Products must have identical essential characteristics to the version approved by the Reference Regulatory Authority, and the foreign authorization must have been issued within the last five years.

  Primary Sources

  1. COFEPRIS. "Acuerdo por el que se establece la vía abreviada de trámite para el registro de medicamentos y dispositivos médicos." Diario Oficial de la Federación, September 1, 2025. https://www.cofepris.gob.mx
  2. U.S. Food and Drug Administration. "Generic Drug User Fee Amendments (GDUFA)." FDA.gov, 2025. https://www.fda.gov
  3. European Medicines Agency. "Generic and hybrid applications." EMA.europa.eu, 2025. https://www.ema.europa.eu
  4. World Health Organization. "WHO Prequalification Programme: Medicines." WHO.int, 2025. https://www.who.int/groups/who-prequalification-team-pqt
  5. Secretaría de Salud (Mexico). "Norma Oficial Mexicana NOM-177-SSA1-2013." DOF, 2013. https://www.cofepris.gob.mx

  Related coverage

  • COFEPRIS Drug Approvals: Trends and Market Impact in Oncology 2025
  • COFEPRIS Approval Pathway: Transforming Generic Drugs Market in Mexico
  • Biosimilars in Argentina: ANMAT Approval and Market Growth Analysis 2025